Albert W. Brzeczko
Net Worth

Last updated:

What is Albert W. Brzeczko net worth?

The estimated net worth of Dr. Albert W. Brzeczko is at least $2,875,800 as of 20 Nov 2023. He owns shares worth $15,800 as insider and has received compensation worth at least $2,860,000 in Acura Pharmaceuticals, Inc..

What is the salary of Albert W. Brzeczko?

Dr. Albert W. Brzeczko salary is $220,000 per year as Vice President of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc. in Acura Pharmaceuticals, Inc..

How old is Albert W. Brzeczko?

Dr. Albert W. Brzeczko is 68 years old, born in 1957.

What stocks does Albert W. Brzeczko currently own?

As insider, Dr. Albert W. Brzeczko owns shares in one company:

Company Title Shares Price per share Total value
Acura Pharmaceuticals, Inc. (ACUR) Vice President of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc. 316,000 $0.05 $15,800

What does Acura Pharmaceuticals, Inc. do?

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was incorporated in 1935 and is based in Palatine, Illinois.

ACUR logo
ACUR
Acura Pharmaceuticals, Inc.
$0.05

Albert W. Brzeczko insider trading

Acura Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Unit (2021 Plan) 40,000 $0.01 $400
Option
Common Stock 40,000 $0.01 $400
Option
Restricted Stock Unit (2017 Plan) 34,000 N/A N/A
Option
Common Stock 34,000 N/A N/A
Option
Restricted Stock Unit (2017 Plan) 34,000 $0.01 $340
Option
Restricted Stock Unit (2017 Plan) 9,333 $0.01 $93
Option
Common Stock 43,333 N/A N/A
Option
Common Stock 43,334 N/A N/A
Option
Restricted Stock Unit (2017 Plan) 34,000 N/A N/A
Option
Restricted Stock Unit (2017 Plan) 9,334 $0.01 $93
Option
Common Stock 9,334 $0.01 $93
Option
Restricted Stock Unit (2017 Plan) 9,334 $0.01 $93
Purchase
Common Stock 300,000 $0.1 $30,000
Purchase
Common Stock 2,000 $0.47 $940
Purchase
Common Stock 1,000 $0.47 $470
Purchase
Common Stock 1,000 $0.47 $470
Purchase
Common Stock 2,000 $0.47 $940
Purchase
Common Stock 1,000 $0.47 $470
Purchase
Common Stock 1,000 $0.47 $470
Purchase
Common Stock 1,800 $0.48 $864
Purchase
Common Stock 1,000 $0.47 $470
Purchase
Common Stock 2,000 $1.2 $2,400
Purchase
Common Stock 1,215 $1.7 $2,066
Purchase
Common Stock 1,000 $2.55 $2,550

Acura Pharmaceuticals key executives

Acura Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:

  • Dr. Albert W. Brzeczko (68) Vice President of Pharmaceutical Sciences of Acura Pharmaceutical Technologies, Inc.
  • Mr. Peter A. Clemens (72) Senior Vice President, Chief Financial Officer & Sec.
  • Mr. Robert B. Jones (66) Chief Executive Officer, Pres & Director